

P450R Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP6518a**Specification**

P450R Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [P16435](#)**P450R Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 5447**Other Names**

NADPH--cytochrome P450 reductase, CPR, P450R, POR, CYPOR

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6518a](/products/AP6518a) was selected from the N-term region of human P450R. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

P450R Antibody (N-term) Blocking Peptide - Protein Information**Name** POR {ECO:0000255|HAMAP-Rule:MF_03212}**Synonyms** CYPOR**Function**

This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.

Cellular Location

Endoplasmic reticulum membrane {ECO:0000255|HAMAP-Rule:MF_03212}; Single-pass membrane protein {ECO:0000255|HAMAP-Rule:MF_03212}; Cytoplasmic side {ECO:0000255|HAMAP-Rule:MF_03212}

P450R Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

P450R Antibody (N-term) Blocking Peptide - Images

P450R Antibody (N-term) Blocking Peptide - Background

P450R is an endoplasmic reticulum membrane oxidoreductase with an FAD-binding domain and a flavodoxin-like domain. The protein binds two cofactors, FAD and FMN, which allow it to donate electrons directly from NADPH to all microsomal P450 enzymes. Mutations in its gene have been associated with various diseases, including apparent combined P450C17 and P450C21 deficiency, amenorrhea and disordered steroidogenesis, congenital adrenal hyperplasia and Antley-Bixler syndrome.

P450R Antibody (N-term) Blocking Peptide - References

Fukami,M., J. Clin. Endocrinol. Metab. 94 (5), 1723-1731 (2009)Mast,N., Arch. Biochem. Biophys. 483 (1), 81-89 (2009)Brenner,S., FEBS J. 275 (18), 4540-4557 (2008)